Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ONCT | US
0.66
45.64%
Healthcare
Biotechnology
30/06/2024
21/10/2024
2.09
1.54
2.37
1.49
Oncternal Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216 a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins which is in Phase 1/2 clinical trial. It is also developing ONCT-808 a chimeric antigen receptor T-cells (CAR-T) which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors as well as targets ROR1; and ONCT-534 a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego California.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
248.6%1 month
195.4%3 months
181.6%6 months
134.7%-
-
0.25
0.01
0.01
0.15
0.85
-
-
6.19M
6.19M
-
-1.11K
-
655.70
-118.06
0.19
0.63
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.32
Range1M
1.32
Range3M
6.40
Rel. volume
8.61
Price X volume
2.12M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Portage Biotech Inc | PRTG | Biotechnology | 5.83 | 6.11M | -4.89% | 0.25 | 1.47% |
Hoth Therapeutics Inc | HOTH | Biotechnology | 0.88 | 6.08M | -5.22% | n/a | 0.44% |
Xenetic Biosciences Inc | XBIO | Biotechnology | 3.765 | 5.81M | -1.44% | n/a | 0.00% |
PALISADE BIO INC | PALI | Biotechnology | 3.91 | 5.41M | 0.51% | n/a | 5.06% |
ERNA | ERNA | Biotechnology | 0.9899 | 5.36M | -2.95% | n/a | -577.12% |
XORTX Therapeutics Inc. Common Stock | XRTX | Biotechnology | 1.71 | 5.15M | -9.04% | n/a | 3.09% |
BIONOMICS LIMITED/FI | BNOX | Biotechnology | 0.2955 | 5.12M | -1.53% | n/a | 0.59% |
180 Life Sciences Corp | ATNF | Biotechnology | 4.97 | 5.10M | -1.19% | n/a | -105.81% |
Molecular Templates Inc | MTEM | Biotechnology | 0.75 | 4.94M | 0.00% | n/a | 155.07% |
QLGN | QLGN | Biotechnology | 0.1825 | 4.93M | 9.15% | n/a | -39.04% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.15 | 0.53 | Cheaper |
Ent. to Revenue | 0.85 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.25 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 181.62 | 72.80 | Riskier |
Debt to Equity | 0.01 | -1.23 | Expensive |
Debt to Assets | 0.01 | 0.25 | Cheaper |
Market Cap | 6.19M | 3.66B | Emerging |